2.50
Hdl Handle:
http://hdl.handle.net/2336/14488
Title:
Review of rabeprazole in the treatment of gastro-oesophageal reflux disease
Authors:
Thjodleifsson, Bjarni
Citation:
Expert Opin Pharmacother 2004, 5(1):137-49
Issue Date:
1-Jan-2004
Abstract:
Gastro-oesophageal reflux disease (GERD) is an increasing health problem in developed countries and is associated with enormous costs in terms of reduced quality of life, loss of productivity, health expenses and mortality. The gastrointestinal disease with the highest annual direct costs in the US (in the year 2000) was GERD (9.3 billion US dollars). GERD is primarily a motility disorder of the oesophagus, however, there are no available promotility drugs on the market. The main symptoms are heartburn and acid regurgitation arising from the reflux of gastric acid, which is the only factor at present suited for pharmacological intervention. The proton pump inhibitors (PPIs) give optimal benefit in the treatment of GERD. The sales of PPIs in the year 2002 amounted to 12 billion US dollars in North America and 4 billion US dollars in Europe and the sales have been increasing by > 10% annually. This paper reviews the use of PPIs in the treatment of GERD with particular focus on one of the newer agents, rabeprazole.
Description:
To access publisher full text version of this article. Please click on the hyperlink in Additional Link field
Additional Links:
http://dx.doi.org/10.1517/14656566.5.1.137

Full metadata record

DC FieldValue Language
dc.contributor.authorThjodleifsson, Bjarni-
dc.date.accessioned2007-11-06T10:36:21Z-
dc.date.available2007-11-06T10:36:21Z-
dc.date.issued2004-01-01-
dc.date.submitted2007-11-06-
dc.identifier.citationExpert Opin Pharmacother 2004, 5(1):137-49en
dc.identifier.issn1465-6566-
dc.identifier.pmid14680443-
dc.identifier.doi10.1517/14656566.5.1.137-
dc.identifier.otherGAS12-
dc.identifier.urihttp://hdl.handle.net/2336/14488-
dc.descriptionTo access publisher full text version of this article. Please click on the hyperlink in Additional Link fielden
dc.description.abstractGastro-oesophageal reflux disease (GERD) is an increasing health problem in developed countries and is associated with enormous costs in terms of reduced quality of life, loss of productivity, health expenses and mortality. The gastrointestinal disease with the highest annual direct costs in the US (in the year 2000) was GERD (9.3 billion US dollars). GERD is primarily a motility disorder of the oesophagus, however, there are no available promotility drugs on the market. The main symptoms are heartburn and acid regurgitation arising from the reflux of gastric acid, which is the only factor at present suited for pharmacological intervention. The proton pump inhibitors (PPIs) give optimal benefit in the treatment of GERD. The sales of PPIs in the year 2002 amounted to 12 billion US dollars in North America and 4 billion US dollars in Europe and the sales have been increasing by > 10% annually. This paper reviews the use of PPIs in the treatment of GERD with particular focus on one of the newer agents, rabeprazole.en
dc.language.isoenen
dc.publisherAshley Publicationsen
dc.relation.urlhttp://dx.doi.org/10.1517/14656566.5.1.137en
dc.subject.mesh2-Pyridinylmethylsulfinylbenzimidazolesen
dc.subject.meshAnti-Ulcer Agentsen
dc.subject.meshBenzimidazolesen
dc.subject.meshClinical Trialsen
dc.subject.meshCost-Benefit Analysisen
dc.subject.meshDrug Interactionsen
dc.subject.meshGastric Aciden
dc.subject.meshGastroesophageal Refluxen
dc.subject.meshOmeprazoleen
dc.subject.meshProton Pumpsen
dc.titleReview of rabeprazole in the treatment of gastro-oesophageal reflux diseaseen
dc.typeArticleen
dc.identifier.journalExpert opinion on pharmacotherapyen
dc.format.digYES-
All Items in Hirsla are protected by copyright, with all rights reserved, unless otherwise indicated.